Guinea-Bissau Halts US-Funded Hepatitis B Vaccine Study Amid Ethics & Sovereignty Clash
A contentious US-funded study on hepatitis B vaccination in Guinea-Bissau has been suspended, local officials confirm, sparking a diplomatic disagreement with American health authorities. While Guinea-Bissau's newly appointed Minister of Health, Quinhin Nantote, stated the trial was "cancelled or suspended" due to insufficient scientific review, the US Department of Health and Human Services (HHS) insists the study will proceed as planned. This conflict highlights deep ethical concerns regarding international research practices and underscores the principle of national sovereignty in vulnerable nations.
The Controversial Study Design and Ethical Concerns
The proposed study, led by Danish researchers, aimed to investigate the long-term health effects of hepatitis B vaccination by administering the vaccine to 7,000 infants at birth and withholding it from another 7,000 until six weeks of age. This design immediately drew criticism, as the World Health Organization (WHO) recommends immediate vaccination of all newborns within 24 hours of birth. Medical experts, including Dr. Abdulhammad Babatunde from Nigeria, likened the design to historical ethical failures like the Tuskegee study, emphasizing that control groups must receive the standard of care. Infants in Guinea-Bissau currently receive the shot at six weeks, but the country plans to roll out newborn vaccination by 2028.
Sovereignty and the Africa CDC's Stance
The Africa Centres for Disease Control and Prevention (Africa CDC) has backed Guinea-Bissau's decision, with Director-General Jean Kaseya asserting that the power to halt such a trial rests squarely with the host nation. "It’s the sovereignty of the country," Kaseya declared, further announcing that an Africa CDC team would assist Guinea-Bissau in reviewing the study, inviting Danish and US officials to join. This stance, however, was met with sharp rebuke from HHS, whose spokesperson Andrew Nixon dismissed Africa CDC's claims as a "public-relations campaign" and questioned its credibility. Kaseya refuted these accusations, pointing to senior HHS officials' alleged unawareness of Nixon's statement and the Africa CDC's vital role in global health.
Unapproved Changes and Oversight Lapses
Further complicating the matter, the study's initial approval by Guinea-Bissau’s ethics committee (CNEPS) on November 5th was for an earlier version. Subsequent significant changes made by the researchers were reportedly not re-approved. The interim director of CNEPS confirmed that the initially approved version did not detail withholding vaccines from newborns, which is the core ethical concern. Notably, the Danish researchers did not appear to seek approval from ethics boards in Denmark or the US, as typically required by the Helsinki Declaration for both sponsoring and host countries.
Context of Vulnerability and Future Implications
The situation is particularly sensitive given Guinea-Bissau's recent political instability, including a coup in November, and its status as one of the world's poorest nations. The country faces severe health challenges, including high maternal mortality, prevalent malaria, and limited access to basic services like water and sanitation. Critics argue that funding should focus on improving vaccine coverage, not using children as "lab rats." Professor Gavin Yamey of Duke Global Health Institute stressed the paramount importance of Guinea-Bissau's Ministry of Health in protecting its citizens. The unfolding events underscore the crucial need for equitable partnerships and stringent ethical oversight in global health research, ensuring that studies genuinely serve the needs and respect the sovereignty of host communities.